文献速递结核与非结核分枝杆菌

巴西密切接触者中进展为结核病的转录组特征

Transcriptomic Signatures of Progression to Tuberculosis Disease Among Close Contacts in Brazil.
PubMed 文献 · J Infect Dis · 2024-01-01

在巴西纳入1854名成人培养确诊肺结核患者的密切接触者,随访24个月,基线用实时定量PCR检测20种既往验证的血转录组特征。25人进展为结核病,其中13例微生物学确诊;多数特征在6个月内预后表现最佳,7种特征在6个月内、3种在9个月内达到世界卫生组织预后测试目标产品概况的最低标准,12个月及以上均未达标。

要点

  • 密切接触者中25/1854进展为结核病,其中13例微生物学确诊。
  • 基线血转录组特征对结核病的预后表现以诊断后6个月内最佳。
  • 7种特征在6个月内、3种在9个月内达到WHO预后测试目标产品概况最低标准,12个月及以上均未达标。

核心结论

  • 血转录组特征可能有助于预测结核暴露接触者在检测后9个月内的结核病风险,以指导预防性治疗的实施。

研究设计与样本

  • 在巴西纳入成人培养确诊肺结核患者的密切接触者(每周暴露≥4小时),随访24个月,症状触发式排查结核病。
  • 基线用实时定量聚合酶链反应检测20种既往验证的血结核转录组特征,用受试者工作特征曲线分析6、9、12和24个月随访时的预后性能。

主要发现

  • 2015年6月至2019年6月共纳入1854名密切接触者,25人进展为结核病,其中13例为微生物学确诊。
  • 1789名密切接触者测定了基线转录组特征评分。
  • 所有特征的预后性能在诊断后6个月内最佳。
  • 7种特征(Gliddon4、Suliman4、Roe3、Roe1、Penn-Nicholson6、Francisco2和Rajan5)在6个月内达到世界卫生组织预后测试目标产品概况的最低标准。
  • 3种特征(Gliddon4、Rajan5和Duffy9)在9个月内达到目标产品概况阈值,12个月及以上随访均无特征达到该阈值。

关键数值与推荐

  • 7种特征(Gliddon4、Suliman4、Roe3、Roe1、Penn-Nicholson6、Francisco2和Rajan5)在6个月内达到世界卫生组织预后测试目标产品概况的最低标准。
  • 3种特征(Gliddon4、Rajan5和Duffy9)在9个月内达到世界卫生组织预后测试目标产品概况的最低标准。
  • 12个月及以上随访无特征达到世界卫生组织预后测试目标产品概况阈值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 5% of people infected with Mycobacterium tuberculosis progress to tuberculosis (TB) disease without preventive therapy. There is a need for a prognostic test to identify those at highest risk of incident TB so that therapy can be targeted. We evaluated host blood transcriptomic signatures for progression to TB disease. METHODS: Close contacts (≥4 hours of exposure per week) of adult patients with culture-confirmed pulmonary TB were enrolled in Brazil. Investigation for incident, microbiologically confirmed, or clinically diagnosed pulmonary or extrapulmonary TB disease through 24 months of follow-up was symptom triggered. Twenty previously validated blood TB transcriptomic signatures were measured at baseline by real-time quantitative polymerase chain reaction. Prognostic performance for incident TB was tested by receiver operating characteristic curve analysis at 6, 9, 12, and 24 months of follow-up. RESULTS: Between June 2015 and June 2019, 1854 close contacts were enrolled. Twenty-five progressed to incident TB, of whom 13 had microbiologically confirmed disease. Baseline transcriptomic signature scores were measured in 1789 close contacts. Prognostic performance for all signatures was best within 6 months of diagnosis. Seven signatures (Gliddon4, Suliman4, Roe3, Roe1, Penn-Nicholson6, Francisco2, and Rajan5) met the minimum World Health Organization target product profile for a prognostic test through 6 months and 3 signatures (Gliddon4, Rajan5, and Duffy9) through 9 months. None met the target product profile threshold through ≥12 months of follow-up. CONCLUSIONS: Blood transcriptomic signatures may be useful for predicting TB risk within 9 months of measurement among TB-exposed contacts to target preventive therapy administration.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mendelsohn SC, Andrade BB, Mbandi SK, et al. Transcriptomic Signatures of Progression to Tuberculosis Disease Among Close Contacts in Brazil. J Infect Dis. 2024. PMID: 38709708. doi:10.1093/infdis/jiae237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。